Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9125204 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL6960167 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL76489 | 0.83 | ALDH1A1 (0.67) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL6551314 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| Hydrochloric Acid SCHEMBL27693713 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL6551386 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL2555480 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL19696409 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL12262968 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HSD17B10HDAC3CA12CA1 | |
| SCHEMBL8415304 | 0.78 | GAA (0.52) | ALDH1A1HSD17B10HDAC3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313713-B1 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | ORTHO MCNEIL PHARM INC (US) | 2008-06-11 | — | — | EP | claimed |
| CN-1468225-A | 4-pyrimidineamine derivatives, pharmaceutical compositions and related methods | ����-������ҩƷ��˾ | 2004-01-14 | — | — | CN | claimed |
| US-20040006094-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | GRANT ELFRIDA R (US) | 2004-01-08 | — | — | US | claimed |
| US-20030212079-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | GRANT ELFRIDA R (US) | 2003-11-13 | — | — | US | claimed |
| EP-1313713-A2 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| US-20030008883-A1 | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-09 | — | — | US | claimed |
| WO-2002012198-A2 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20050203092-A1 | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | BENJAMIN ELFRIDA R (US) | 2005-09-15 | — | — | US | disclosed |
| CN-1468225-A | 4-pyrimidineamine derivatives, pharmaceutical compositions and related methods | ����-������ҩƷ��˾ | 2004-01-14 | — | — | CN | disclosed |
| US-20040006094-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | GRANT ELFRIDA R (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030212079-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | GRANT ELFRIDA R (US) | 2003-11-13 | — | — | US | disclosed |
| EP-1313713-A2 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030008883-A1 | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-09 | — | — | US | disclosed |
| WO-2002012198-A2 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006094-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | CASP3, CASP5, CASP4 | ALDH1A1 1306/4885HSD17B10 4556/4885HDAC3 1903/4885 |
| US-20030008883-A1 | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | CASP3, CASP5, CASP4 | ALDH1A1 1306/4885HSD17B10 4556/4885HDAC3 1903/4885 |
| US-20030212079-A1 | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods | CASP3, CASP5, CASP4 | ALDH1A1 1306/4885HSD17B10 4556/4885HDAC3 1903/4885 |
| US-20050203092-A1 | 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods | CASP3, CASP5, CASP4 | ALDH1A1 1306/4885HSD17B10 4556/4885HDAC3 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.